高级搜索
立即登录 | 免费注册
当前位置 >   首页 > 医药资讯 >  医学资讯  > 医学资讯内容

维生素E、C无预防白内障作用

Vitamins E, C Have No Effect on Cataract Development

BY JEFFREY S. EISENBERG 2010-11-08 【发表评论】
中文 | ENGLISH | 打印| 推荐给好友
Elsevier Global Medical News
Breaking News 爱思唯尔全球医学资讯
最新进展

Long-term use of high-dose vitamins E and C, alone or combined, has no effect in preventing the development of cataracts in men, according to the latest findings of the Physicians’ Health Study II reported in the November issue of Archives of Ophthalmology.

The PHS II, a randomized, double-masked, placebo-controlled trial, studied the effectiveness of vitamins E and C and a multivitamin in preventing cancer and cardiovascular disease among 14,641 apparently healthy U.S. male physicians aged 50 years or older. Incident cataract was a secondary end point.

Prospective observational studies have suggested that intake of vitamins E and C helps prevent the oxidative damage to the lens that leads to cataract. However, completed randomized trials have shown little beneficial effect of either vitamin, whether used alone or in combination with other supplements – even with as many as 10 years of treatment.

For this study, Dr. William G. Christen from Brigham and Women’s Hospital and Harvard Medical School, Boston, and his colleagues randomized 11,545 subjects as follows: 5,771 to receive 400 IU of vitamin E every other day, 5,774 to receive a vitamin E placebo every other day, 5,779 to receive 500 mg of vitamin C daily, and 5,746 to receive a vitamin C placebo daily (Arch. Ophthalmol. 2010;128:1397-1405). The researchers distributed baseline characteristics, including risk factors, evenly among the groups.

During a mean follow-up of 8 years, there were 579 cataracts in the vitamin E group, 595 in the vitamin E placebo group, 593 in the vitamin C group, and 581 in the vitamin C placebo group. There appeared little difference among patients with known or possible risk factors. There were 801 cataract extractions during this period.

Supplementation with vitamins E and C had no significant effect on diagnosed cataract or extraction, or on cataract subtype (nuclear, cortical, or posterior subcapsular). In the vitamin C group, there was a possible, but statistically nonsignificant, trend toward increased risk in those with a reported history of cardiovascular disease.

When interpreting these results, the researchers caution that several factors must be considered. For example, participants were generally well nourished, so findings might not apply to less well nourished populations. Also, the doses of both vitamins used were higher than normal dietary levels and levels used in observational studies, so even higher doses would probably yield no benefits. Although follow-up lasted 8 years, cataracts develop slowly over many years and may require longer periods of treatment, and possibly treatment at younger ages.

Finally, the PHS II excluded participants with known cataract. Many previous trials included patients with lens opacities at baseline, so intervention in those trials may have occurred too late in the disease process to have a material effect on rates of cataract, the researchers said.

The authors reported no financial disclosures. Support for the study came from grants funded by the U.S. National Eye Institute, the U.S. National Institute on Aging, the U.S. National Institutes of Health, and BASF Corp. The study was sponsored by BASF, Wyeth Pharmaceuticals, and DSM Nutritional Products, which had no role in the design and conduct of the study; in the collection, analysis, and interpretation of the data; or in the preparation, review, and approval of the manuscript.

Copyright (c) 2010 Elsevier Global Medical News. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

《眼科学纪要》(Archives of Ophthalmology)11月刊载的PHS II研究显示,长期应用大剂量维生素EC(不管是单用还是联用)对预防男性白内障的发生并无帮助。

 
本研究为随机、双盲、安慰剂对照研究,共入选14,64150岁以上的美国男性健康医生(排除已知患有白内障者),旨在探讨维生素EC及复合维生素对癌症和心血管疾病的预防作用。次要研究终点为白内障发生率。
 
11,545名受试者被随机分组:维生素E(400 IU,每隔1)5,771名,维生素E安慰剂组5,774名,维生素C(500 mg,每天1 )5,779名,维生素C安慰剂组5,746 (Arch. Ophthalmol. 2010;128:1397-1405)。基线特征(包括危险因素)在各组中的分布平均。
 
平均随访8年期间,维生素E组发生白内障的病例为579例,维生素E安慰剂组为595例,维生素C组为593例,维生素C安慰剂组为581例。已知或可能具有危险因素的患者之间的差异细微。在这期间,共有801例患者行白内障摘除术。
 
补充维生素EC对白内障、白内障摘除及白内障亚型(核性、皮质性和后囊下)并无显著影响。在维生素C组,具有心血管病史的受试者存在可能的、但无统计学意义的风险增加趋势。
 
研究者提醒,在解读本研究结果时需考虑一些因素。例如,受试者的营养状况良好,因此本研究结果可能不适用于营养状况不佳的人群。另外,本研究中两种维生素的剂量水平高于正常膳食水平及观察性研究中所用的水平,因此即使应用更高剂量可能也不会产生任何益处。
 
本研究由BASF公司、惠氏制药公司和帝斯曼营养产品部申办,并获得美国国立眼科研究所、美国国立老化研究所、美国国立卫生研究院和BASF公司的资金支持。申办者未参与研究的设计及开展、数据的收集、分析及解读、以及手稿的撰写、审查和批准。研究者声明无经济利益冲突。
 
爱思唯尔 版权所有

Subjects:
gerontology, ophthalmology
学科代码:
老年病学, 眼科学

请登录后发表评论, 点击此处登录。

病例分析 <span class="ModTitle_Intro_Right" id="EPMI_Home_MedicalCases_Intro_div" onclick="javascript:window.location='http://www.elseviermed.cn/tabid/127/Default.aspx'" onmouseover="javascript:document.getElementById('EPMI_Home_MedicalCases_Intro_div').style.cursor='pointer';document.getElementById('EPMI_Home_MedicalCases_Intro_div').style.textDecoration='underline';" onmouseout="javascript:document.getElementById('EPMI_Home_MedicalCases_Intro_div').style.textDecoration='none';">[栏目介绍]</span>  病例分析 [栏目介绍]

 王燕燕 王曙

上海交通大学附属瑞金医院内分泌科

患者,女,69岁。2009年1月无明显诱因下出现乏力,当时程度较轻,未予以重视。2009年3月患者乏力症状加重,尿色逐渐加深,大便习惯改变,颜色变淡。4月18日入我院感染科治疗,诉轻度头晕、心慌,体重减轻10kg。无肝区疼痛,无发热,无腹痛、腹泻、腹胀、里急后重,无恶性、呕吐等。入院半月前于外院就诊,查肝功能:ALT 601IU/L,AST 785IU/L,TBIL 97.7umol/L,白蛋白 41g/L,甲状腺功能:游离T3 30.6pmol/L,游离T4 51.9pmol/L,心电图示快速房颤。
 

疾病资源中心  疾病资源中心
医学数据库  医学数据库



友情链接:中文版柳叶刀 | MD CONSULT | Journals CONSULT | Procedures CONSULT | eClips CONSULT | Imaging CONSULT | 论文吧 | 世界医学书库 医心网 | 前沿医学资讯网

公司简介 | 用户协议 | 条件与条款 | 隐私权政策 | 网站地图 | 联系我们

 互联网药品信息服务资格证书 | 卫生局审核意见通知书 | 药监局行政许可决定书 
电信与信息服务业务经营许可证 | 京ICP证070259号 | 京ICP备09068478号

Copyright © 2009 Elsevier.  All Rights Reserved.  爱思唯尔版权所有